Peran Apolipoprotein B, Apolipoprotein A, dan Rasio ApoA/ApoB sebagai Prediktor Terjadinya Demensia pada Kelompok Lanjut Usia

Alfred Sutrisno Sim; Alexander Halim Santoso; Farell Christian Gunaidi; Khalisya Alifia; Vincent Aditya; Edwin Destra

doi:10.55606/jurrike.v4i1.4891

Authors

Alfred Sutrisno Sim Universitas Tarumanagara
Alexander Halim Santoso Universitas Tarumanagara
Farell Christian Gunaidi Universitas Atmajaya
Khalisya Alifia Universitas Tarumanagara
Vincent Aditya Universitas Tarumanagara
Edwin Destra Universitas Atmajaya

DOI:

https://doi.org/10.55606/jurrike.v4i1.4891

Keywords:

Apolipoprotein A, Apolipoprotein B, Cognitive Function, Dementia

Abstract

Neurocognitive disorders, particularly dementia, affect various cognitive functions such as memory, attention, language, learning, and problem-solving, with the elderly population being the most impacted. The prevalence of dementia is projected to rise to 131 million cases by 2050, posing significant social and economic implications. This study employed a cross-sectional method to evaluate the role of Apolipoprotein A (APOA) and Apolipoprotein B (APOB) in the diagnosis and prevention of dementia in older adults. The results showed that Apolipoprotein A was not significantly correlated with MMSE scores, indicating no clear relationship between APOA and cognitive function. In contrast, Apolipoprotein B demonstrated a significant negative correlation with MMSE, suggesting that increased APOB levels are associated with cognitive decline. Elevated ApoB, linked to increased LDL and oxidative stress, correlated with reduced cognitive function, whereas ApoA, the main component of HDL, is associated with neuroprotective effects. These findings underscore the importance of monitoring lipid profiles, including ApoA and ApoB, in the prevention and management of dementia in the elderly.

Downloads

Download data is not yet available.

References

Alizadeh-Fanalou, S., Nazarizadeh, A., Alian, F., Faraji, P., Sorori, B., & Khosravi, M. (2020). Small dense low-density lipoprotein-lowering agents. Biological Chemistry, 401(10), 1101–1121. https://doi.org/10.1515/hsz-2019-0426

Anusheel, Avula, S. N., Joseph, K.-L.-T. N., Onuchukwu, C. V., Thondamala, V., Shrivastava, S., Namburi, A. R., & Mohammed, L. (2022). The role of high-density lipoprotein in lowering risk of dementia in the elderly: A review. Cureus, 14(4), e24374. https://doi.org/10.7759/cureus.24374

Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021). Apolipoprotein B and cardiovascular disease: Biomarker and potential therapeutic target. Metabolites, 11(10). https://doi.org/10.3390/metabo11100690

Cao, Q., Tan, C.-C., Xu, W., Hu, H., Cao, X.-P., Dong, Q., Tan, L., & Yu, J.-T. (2020). The prevalence of dementia: A systematic review and meta-analysis. Journal of Alzheimer’s Disease: JAD, 73(3), 1157–1166. https://doi.org/10.3233/JAD-191092

Churashova, I. A., Sokolov, A. V., Kostevich, V. A., Gorbunov, N. P., Runova, O. L., Firova, E. M., & Vasilyev, V. B. (2021). Myeloperoxidase/high-density lipoprotein cholesterol ratio in patients with arterial hypertension and chronic coronary heart disease. Medical Academic Journal, 21(2), 75–86. https://doi.org/10.17816/MAJ71486

Devaraj, S., Semaan, J. R., & Jialal, I. (2024). Biochemistry, apolipoprotein B. In StatPearls. http://www.ncbi.nlm.nih.gov/pubmed/27114384

Dorobanțu, M., Halațiu, V.-B., Gheorghe-Fronea, O., Bala, C.-G., Moldovan, H., Irinel-Parepa, R., Rodean, I.-P., Benedek, I., & Benedek, T. (2023). The association between apolipoprotein B, cardiovascular risk factors and subclinical atherosclerosis—Findings from the SEPHAR national registry on hypertension in Romania. International Journal of Molecular Sciences, 24(3). https://doi.org/10.3390/ijms24032813

Emmady, P. D., Schoo, C., & Tadi, P. (2024). Major neurocognitive disorder (dementia). In StatPearls. http://www.ncbi.nlm.nih.gov/pubmed/25266297

Ezkurdia, A., Ramírez, M. J., & Solas, M. (2023). Metabolic syndrome as a risk factor for Alzheimer’s disease: A focus on insulin resistance. International Journal of Molecular Sciences, 24(5), 4354. https://doi.org/10.3390/ijms24054354

Fan, J., Wang, H., Ye, G., Cao, X., Xu, X., Tan, W., & Zhang, Y. (2020). Letter to the editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism: Clinical and Experimental, 107(January). https://doi.org/10.1016/j.metabol.2020.154243

Farina, N., Jacobs, R., Turana, Y., Fitri, F. I., Schneider, M., Theresia, I., Docrat, S., Sani, T. P., Augustina, L., Albanese, E., Comas-Herrera, A., Du Toit, P., Ferri, C. P., Govia, I., Ibnidris, A., Knapp, M., & Banerjee, S. (2023). Comprehensive measurement of the prevalence of dementia in low- and middle-income countries: STRiDE methodology and its application in Indonesia and South Africa. BJPsych Open, 9(4), 1–7. https://doi.org/10.1192/bjo.2023.76

Farzam, K., Zubair, M., & Senthilkumaran, S. (2024). Lipoprotein A. In StatPearls. http://www.ncbi.nlm.nih.gov/pubmed/29262744

Gong, J., Harris, K., Peters, S. A. E., & Woodward, M. (2022). Serum lipid traits and the risk of dementia: A cohort study of 254,575 women and 214,891 men in the UK Biobank. EClinicalMedicine, 54, 101695. https://doi.org/10.1016/j.eclinm.2022.101695

Johannesen, C. D. L., Langsted, A., Nordestgaard, B. G., & Mortensen, M. B. (2024). Excess apolipoprotein B and cardiovascular risk in women and men. Journal of the American College of Cardiology, 83(23), 2262–2273. https://doi.org/10.1016/j.jacc.2024.03.423

Kanonidou, C. (2021). Small dense low-density lipoprotein: Analytical review. Clinica Chimica Acta, 520(June), 172–178. https://doi.org/10.1016/j.cca.2021.06.012

Karjalainen, M. K., Holmes, M. V., Wang, Q., Anufrieva, O., Kähönen, M., Lehtimäki, T., Havulinna, A. S., Kristiansson, K., Salomaa, V., Perola, M., Viikari, J. S., Raitakari, O. T., Järvelin, M.-R., Ala-Korpela, M., & Kettunen, J. (2020). Apolipoprotein A-I concentrations and risk of coronary artery disease: A Mendelian randomization study. Atherosclerosis, 299, 56–63. https://doi.org/10.1016/j.atherosclerosis.2020.02.002

Konrad, E., Güralp, O., Shaalan, W., Elzarkaa, A. A., Moftah, R., Alemam, D., Malik, E., & Soliman, A. A. (2020). Correlation of elevated levels of lipoprotein(a), high-density lipoprotein and low-density lipoprotein with severity of preeclampsia: A prospective longitudinal study. Journal of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and Gynaecology, 40(1), 53–58. https://doi.org/10.1080/01443615.2019.1603214

Martin, L., Boutwell, B. B., Messerlian, C., & Adams, C. D. (2024). Mendelian randomization reveals apolipoprotein B shortens healthspan and possibly increases risk for Alzheimer’s disease. Communications Biology, 7(1), 230. https://doi.org/10.1038/s42003-024-05887-2

Mehta, A., & Shapiro, M. D. (2022). Apolipoproteins in vascular biology and atherosclerotic disease. Nature Reviews Cardiology, 19(3), 168–179. https://doi.org/10.1038/s41569-021-00613-5

Mkhitaryan, E. A., Vorobieva, N. M., Tkacheva, O. N., Kotovskaya, Y. V., Koberskaya, N. N., Selezneva, E. V., & Ovcharova, L. N. (2022). The prevalence of cognitive impairment and their association with socioeconomic, demographic and anthropometric factors and geriatric syndromes in people over 65 years of age: Data from the Russian epidemiological study EVKALIPT. Neurology, Neuropsychiatry, Psychosomatics, 14(3), 44–53. https://doi.org/10.14412/2074-2711-2022-3-44-53

Opoku, S., Gan, Y., Yobo, E. A., Tenkorang-Twum, D., Yue, W., Wang, Z., & Lu, Z. (2021). Awareness, treatment, control, and determinants of dyslipidemia among adults in China. Scientific Reports, 11(1), 10056. https://doi.org/10.1038/s41598-021-89401-2

Paula-Lima, A. C., Tricerri, M. A., Brito-Moreira, J., Bomfim, T. R., Oliveira, F. F., Magdesian, M. H., Grinberg, L. T., Panizzutti, R., & Ferreira, S. T. (2009). Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. The International Journal of Biochemistry & Cell Biology, 41(6), 1361–1370. https://doi.org/10.1016/j.biocel.2008.12.003

Picard, C., Nilsson, N., Labonté, A., Auld, D., Rosa-Neto, P., Alzheimer’s Disease Neuroimaging Initiative, Ashton, N. J., Zetterberg, H., Blennow, K., Breitner, J. C. B., Villeneuve, S., Poirier, J., & PREVENT-AD research group. (2022). Apolipoprotein B is a novel marker for early tau pathology in Alzheimer’s disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 18(5), 875–887. https://doi.org/10.1002/alz.12442

Pokharel, Y., Mouhanna, F., Nambi, V., Virani, S. S., Hoogeveen, R., Alonso, A., Heiss, G., Coresh, J., Mosley, T., Gottesman, R. F., Ballantyne, C. M., & Power, M. C. (2019). ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology, 92(22), e2580–e2593. https://doi.org/10.1212/WNL.0000000000007574

Proitsi, P. (2021). The key role of apolipoprotein B in major vascular diseases and longevity. The Lancet Healthy Longevity, 2(6), e302–e303. https://doi.org/10.1016/S2666-7568(21)00120-3

Ranson, J. M., Rittman, T., Hayat, S., Brayne, C., Jessen, F., Blennow, K., van Duijn, C., Barkhof, F., Tang, E., Mummery, C. J., Stephan, B. C. M., Altomare, D., Frisoni, G. B., Ribaldi, F., Molinuevo, J. L., Scheltens, P., Llewellyn, D. J., & European Task Force for Brain Health Services. (2021). Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—Part 2 of 6. Alzheimer’s Research & Therapy, 13(1), 169. https://doi.org/10.1186/s13195-021-00895-4

Rasmussen, K. L., & Frikke-Schmidt, R. (2024). The current state of apolipoprotein E in dyslipidemia. Current Opinion in Lipidology, 35(2), 78–84. https://doi.org/10.1097/MOL.0000000000000915

Saczynski, J. S., Tylavsky, F. A., Yaffe, K., Masaki, K., Curb, J. D., Petrovitch, H., White, L., Launer, L. J., & Honolulu-Asia Aging Study. (2014). Higher plasma total cholesterol levels in late life are associated with better cognitive function: The Honolulu-Asia aging study. Journal of the American Geriatrics Society, 62(5), 667–673. https://doi.org/10.1111/jgs.12747

Santos, M. L., Maranhão, R. C., Alves, V. A. F., Ferreira, D. S. A., Maia, M. C. S. F., de Sousa, T. M. S., & Cangussu, L. M. (2023). The role of apolipoprotein A1 in cardiovascular diseases: A review of recent advances. Lipids in Health and Disease, 22(1), 147. https://doi.org/10.1186/s12944-023-01892-8

Schneider, J. A., Arvanitakis, Z., & Bennett, D. A. (2007). Overview and findings from the religious orders study. Current Alzheimer Research, 4(5), 435–443. https://doi.org/10.2174/156720507782108945

Tanaka, H., Hozawa, A., Okamura, T., Kadowaki, T., Murata, K., & Ohkubo, T. (2007). Serum apolipoprotein B and A-I and the risk of stroke and coronary heart disease: The Suita study. Stroke, 38(12), 3138–3144. https://doi.org/10.1161/STROKEAHA.107.494326

Tanaka, M., Tomiyama, N., Hashimoto, M., Sakamoto, S., & Yamaguchi, S. (2019). ApoB/apoA1 ratio as a predictive biomarker for dementia in the elderly. Journal of Alzheimer’s Disease, 70(2), 605–613. https://doi.org/10.3233/JAD-190325

Teichmann, M., & Arendt, T. (2023). Apolipoprotein E isoforms and Alzheimer’s disease: Evidence from experimental and clinical studies. Journal of Molecular Neuroscience, 73(3), 368–378. https://doi.org/10.1007/s12031-023-02132-7

Tucker, R. P., & Gentry, R. N. (2024). The impact of apolipoprotein E on synaptic function in Alzheimer’s disease. Neuroscience Letters, 789, 136862. https://doi.org/10.1016/j.neulet.2024.136862

Wang, X., Lin, M., Lu, J., Shen, X., & Hu, X. (2020). The association between plasma apolipoprotein B and cognitive impairment: A cross-sectional study. Neuropsychiatric Disease and Treatment, 16, 1461–1468. https://doi.org/10.2147/NDT.S247474

Yano, Y., Ahmed, A., & Dutta, R. (2024). Apolipoprotein B as a therapeutic target in cardiovascular disease. Cardiovascular Research, 120(6), 985–997. https://doi.org/10.1093/cvr/cvz276

Zhao, W., Zuo, C., Zhan, L., & Yang, L. (2023). Serum apolipoprotein B and risk of dementia in older adults: A longitudinal cohort study. Frontiers in Neurology, 14, 1162543. https://doi.org/10.3389/fneur.2023.1162543